Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease.

Division of Physiological Medicine, St George's Hospital Medical School, London SW17 0RE, UK.
Thorax (Impact Factor: 8.56). 08/1999; 54(7):581-6. DOI: 10.1136/thx.54.7.581
Source: PubMed

ABSTRACT Methods of classifying chronic obstructive pulmonary disease (COPD) depend largely upon spirometric measurements but disability is only weakly related to measurements of lung function. With the increased use of pulmonary rehabilitation, a need has been identified for a simple and standardised method of categorising disability in COPD. This study examined the validity of the Medical Research Council (MRC) dyspnoea scale for this purpose.
One hundred patients with COPD were recruited from an outpatient pulmonary rehabilitation programme. Assessments included the MRC dyspnoea scale, spirometric tests, blood gas tensions, a shuttle walking test, and Borg scores for perceived breathlessness before and after exercise. Health status was assessed using the St George's Respiratory Questionnaire (SGRQ) and Chronic Respiratory Questionnaire (CRQ). The Nottingham Extended Activities of Daily Living (EADL) score and Hospital Anxiety and Depression (HAD) score were also measured.
Of the patients studied, 32 were classified as having MRC grade 3 dyspnoea, 34 MRC grade 4 dyspnoea, and 34 MRC grade 5 dyspnoea. Patients with MRC grades 1 and 2 dyspnoea were not included in the study. There was a significant association between MRC grade and shuttle distance, SGRQ and CRQ scores, mood state and EADL. Forced expiratory volume in one second (FEV1) was not associated with MRC grade. Multiple logistic regression showed that the determinants of disability appeared to vary with the level of disability. Between MRC grades 3 and 4 the significant covariates were exercise performance, SGRQ and depression score, whilst between grades 4 and 5 exercise performance and age were the major determinants.
The MRC dyspnoea scale is a simple and valid method of categorising patients with COPD in terms of their disability that could be used to complement FEV1 in the classification of COPD severity.

1 Follower
  • [Show abstract] [Hide abstract]
    ABSTRACT: Chronic obstructive pulmonary disease (COPD) is the most extensively studied and researched disease in pulmonology and a cause of significant morbidity, mortality, and financial burden on patient's family and country's economy. Its management continues to be a challenge to both the physician and the patient's family. So far, it is preventable and treatable but not curable. Emphysema, a phenotype of COPD, is the most debilitating condition associated with progressive exercise intolerance and severe dyspnea. Despite decades of research, medical treatments available so far have helped improve quality of life and slowed down the decline in respiratory function but did not significantly improve the survival benefits. Though surgical lung volume reduction (LVR) procedures have shown some promise in context to functional gains and survival but, only in a carefully selected group of patients, bronchoscopic LVR procedures are yet to explore their full potential and limitations. This paper retrospectively studied the developments so far, medical and surgical, with special emphasis on the bronchoscopic procedures of lung volume reduction, and tried to comparatively analyze the risks and benefits of each one of them through various trials and studies done to date.
    12/2014; 2014:757016. DOI:10.1155/2014/757016
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: ABSTRACT Introduction: Multiple disease entities in geriatric patients may exacerbate chronic obstructive pulmonary disease symptoms and lead to functional limitations. The purpose of this study was to assess and compare activities of daily living in geriatric and non-geriatric patients with chronic obstructive pulmonary disease. Materials and Method: Thirty-eight patients with chronic obstructive pulmonary disease were included in this study. The patients were divided into two groups: geriatric (age>65 years) and non-geriatric (age<65 years). Dyspnea level was evaluated using modified Medical Research Council Dyspnea Scale. Activities of daily living were assessed with two performance-based activities of daily living tests: the Glittre Activities of Daily Living Test and the Activities of Daily Living Simulation Test. Results: Pulmonary function and dyspnea levels of geriatric and non-geriatric patients were similar in the study (p>0.05). Glittre Activities of Daily Living Test time was significantly shorter in the non-geriatric patients than in the geriatric patients (p<0.05). Significantly fewer cycles in the Activities of Daily Living Simulation Test were completed by the geriatric patients than by the non-geriatric patients (p<0.05). Conclusion: Activities of daily living performance is reduced in the geriatric patients with moderate to severe chronic obstructive pulmonary disease compared with younger individuals with same disease severity, dyspnea levels and comorbidities. Influences in activities of daily living of the geriatric patients with chronic obstructive pulmonary disease can be revealed as distinctive compared with the adult patients using these activities of daily living tests.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Chronic obstructive pulmonary disease (COPD) is a major cause of chronic morbidity and mortality worldwide, and its epidemiological, clinical, and socioeconomic impact is progressively increasing. A first estimate of the economic burden of COPD in Italy was conducted in 2008 (the SIRIO [Social Impact of Respiratory Integrated Outcomes] study). The aim of the present study is to provide an updated picture of the COPD economic burden in Italy. Sequential patients presenting at the specialist center for the first time during the period 2008-2012 and with record file complete (demographic, clinical, lung function, and therapeutic data; health care resources consumed in the 12 months before the enrollment and for the 3 subsequent years) were selected from the institutional database. Two hundred and seventy-five COPD patients fitting the inclusion criteria were selected (226 males; mean age: 70.9 years [standard deviation: ±8.4 years]; 45.8% were from the north, 25.1% from central Italy, and 29.1% from south Italy). COPD-related average costs per patient in the 12 months before enrollment were as follows: hospitalization: €1,970; outpatient care: €463; pharmaceutical: €499; and indirect costs: €358. Average direct costs and total societal costs were €2,932 and €3,291, respectively. Direct cost was €2,461 (hospitalization: €1,570; outpatient: €344; and pharmaceutical: €547) in the first year of follow-up, while total societal cost was €2,707. No significant difference was reported in any cost category between sexes. The therapeutic approach followed in a specialist center, based on the application of clinical guidelines, has been shown to be a highly effective investment for the long-term management of COPD. A small increase of pharmaceutical costs per year allowed a substantial saving in terms of hospitalizations, costs related to outpatient services, and indirect costs.
    ClinicoEconomics and Outcomes Research 01/2015; 7:153-9. DOI:10.2147/CEOR.S77504

Full-text (2 Sources)

Available from
May 16, 2014